Literature DB >> 18926885

Excitability of small-diameter trigeminal ganglion neurons by 5-HT is mediated by enhancement of the tetrodotoxin-resistant sodium current due to the activation of 5-HT(4) receptors and/or by the inhibition of the transient potassium current.

Y Tsutsui1, M Ikeda, M Takeda, S Matsumoto.   

Abstract

The aims of the present study were to investigate whether the activation of the 5-HT receptor subtypes (5-HT(4) and 5-HT(3)) acted significantly on the modification of the tetrodotoxin-resistant sodium current (I(NaR)) in small-sized rat trigeminal ganglion (TG) neurons and whether the inhibition of the transient K(+) current (I(A)) contributed to the excitability in those neurons. 5-HT applications in at concentrations ranging from 0.01-10 microM significantly increased the peak I(NaR). One micromolar 5-HT application caused the greatest increase in the peak I(NaR) amplitude accompanied by a hyperpolarizing shift in the activation curve. A similar modification of I(NaR) properties was also obtained via the application of the 5-HT(4) receptor agonist, RS 67333, in concentrations ranging from 0.001-1 microM. The largest effects of 5-HT (1 microM) and RS 67333 (0.1 microM) on the modification of I(NaR) were abolished by pretreatment with ICS 205-930 (a 5-HT(3/4) receptor antagonist, 10 microM), which showed no significant effect on the baseline I(NaR). However, ICS 205-930 application at 30 microM caused a significant decrease in the baseline I(NaR). Phenylbiguanide (a 5-HT(3) receptor agonist) did not significantly alter I(NaR) properties when applied in concentrations ranging from 1 to 100 microM. The application of 0.1 microM RS 67333 decreased the transient K(+) current (I(A)) by approximately 31%. The threshold for action potential generation was significantly lower after the application of 0.1 microM RS 67333. Furthermore, 0.1 microM RS 67333 application increased the number of action potentials and the resting membrane potential got more positive, but it decreased the duration of depolarization phase of action potential. In addition, neither the additional application of 1 microM 5-HT in the presence of 10 microM forskolin, a stimulator of adenylyl cyclase, nor the opposite applications of 5-HT and forskolin caused the enhancement of increased I(NaR), which indicates the presence of an 'occluding effect.' These results suggest that the 5-HT-induced modification of I(NaR) is mediated by the activation of 5-HT(4) receptors, involving a cAMP-dependent signaling pathway, and that the inhibition of I(A) following the application of a 5-HT(4) receptor agonist also contributes to the increased number of action potentials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926885     DOI: 10.1016/j.neuroscience.2008.09.024

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

1.  Genome-wide association of an integrated osteoporosis-related phenotype: is there evidence for pleiotropic genes?

Authors:  David Karasik; Ching Lung Cheung; Yanhua Zhou; L Adrienne Cupples; Douglas P Kiel; Serkalem Demissie
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

2.  Serotonin regulates voltage-dependent currents in type I(e(A)) and I(i) interneurons of Hermissenda.

Authors:  Nan Ge Jin; Terry Crow
Journal:  J Neurophysiol       Date:  2011-08-03       Impact factor: 2.714

3.  Light-activated serotonin for exploring its action in biological systems.

Authors:  Adam C Rea; Laura N Vandenberg; Rebecca E Ball; Ashley A Snouffer; Alicia G Hudson; Yue Zhu; Duncan E McLain; Lindsey L Johnston; James D Lauderdale; Michael Levin; Timothy M Dore
Journal:  Chem Biol       Date:  2013-12-12

4.  Effects of acetazolamide on transient K+ currents and action potentials in nodose ganglion neurons of adult rats.

Authors:  Shigeji Matsumoto; Shinki Yoshida; Mizuho Ikeda; Jun Kadoi; Masayuki Takahashi; Takeshi Tanimoto; Junichi Kitagawa; Chikako Saiki; Mamoru Takeda; Yukio Shima
Journal:  CNS Neurosci Ther       Date:  2011-02       Impact factor: 5.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.